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ABSTRACT 
Purpose: The purpose of this study is to perform a systematic review and meta-analysis on 
prevalence of frailty among patients with End-stage renal disease (ESRD). ESRD is 
associated with malnutrition, chronic inflammation, acidemia, impaired hormonal changes, 
and low physical activity, all of which can directly and indirectly contribute to the 
development of frailty. Coexistence of ESRD and frailty has been shown to increase risks of 
adverse health outcomes. Given potential reversibility of frailty, it is important to examine 
frailty status in this high risk population. 
 
Methods: Three databases (Embase, Medline, and CINAHL) were systematically searched 
for studies providing cross-sectional data of prevalence of frailty defined by Cardiovascular 
Health Study (CHS) criteria among ESRD patients. Meta-analysis calculated pooled 
prevalence of frailty according to modifications of CHS criteria. 
 
Results: Of 837 studies identified through the systematic review, seven studies were 
included. Three studies used both objectively measured and self-reported CHS criteria, and 
two studies each used only either criteria. Pooled prevalence of frailty was 36.8% (five 
studies: 95%CI=29.9-44.1%, I2=82.6%, p<0.001) and 67.0% (five studies: 95%CI=58.7-
74.7%, I2=82.6%, p<0.001) according to the objectively measured and self-reported CHS 
criteria, respectively. 
 
Conclusions: More than one third of ESRD patients were frail based on the objectively 
measured CHS criteria, and that prevalence of frailty almost doubled with the CHS criteria 
substituting self-reported physical function questionnaire score for objective measurements. 
Given substantial difference in prevalence of frailty depending on the modifications to CHS 
criteria, this information should be taken into account when evaluating frailty status among 
ESRD population. 
 
Keywords: End-stage renal disease; Hemodialysis; Chronic kidney disease; Frailty; 
Prevalence. 
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INTRODUCTION 
Frailty has been described as an age-related fragile state characterized by a lack of 
physiological reserve with a declined ability to resist stressors,[1,2] leading to increased risks 
of adverse health outcomes including falls,[3] fracture,[4] hospitalization,[5] 
institutionalization,[6] disability,[7] dementia,[8] and poor quality of life.[9] The most 
frequently used definition of frailty is a frailty phenotype that Fried and colleagues originally 
conceptualized in 2001 among community-dwelling people aged 65 years and older from the 
Cardiovascular Health Study (CHS).[2] The criteria consist of five physical components: 
unintentional weight loss, exhaustion, weakness, slow walking speed, and low physical 
activity, and frailty is defined as meeting any three or more of the five components.[2] Frailty 
has been extensively studied in the general population and its weighted overall prevalence 
among community-dwelling people aged 65 or older is approximately 10% with risk factors 
of advanced age and female gender.[10] In contrast, there has been a relatively limited 
amount of research conducted among selected samples, such as institutionalized[11] and 
surgical patients,[12] or those with specific medical conditions such as cardiovascular 
disease,[13] cancers,[14] and HIV.[15] As expected, these high risk populations have been 
shown to have an increased prevalence of frailty.  
 
Chronic kidney disease (CKD) is a condition associated with malnutrition, chronic 
inflammation, acidemia, impaired hormonal changes, and low physical activity,[16-18] all of 
which can directly and indirectly contribute to accelerated aging process, and possibly to the 
development of frailty.[19] Although CKD itself is a predictor of adverse health outcomes, 
coexistence of CKD and frailty has been shown to further increase risks of falls, fractures, 
hospitalization, and mortality.[20-22] Individuals with CKD are at a higher risk of frailty, and 
prevalence of frailty increases as renal function declines, with the highest prevalence among 
patients with end-stage renal disease (ESRD).[22-26]  
 
In light of the fact that frailty is highly common and predicts adverse health outcomes in the 
CKD population, as well as a potential reversibility of frailty by appropriate interventions,[1] 
it is of importance to examine frailty status in the ESRD population, who are at the highest 
risk among CKD patients. The objectives of this systematic review and meta-analysis were to 
perform a systematic search of the literature regarding frailty status in ESRD patients and to 
synthesize pooled estimates of frailty prevalence. This review also paid attention to 
definitions of frailty and their modifications. 
 
METHOD 
Data Source and Search Strategy 
This study was conducted based on a protocol created according to the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.[27] One investigator 
(GK) searched three electronic databases (Embase, Medline, and CINAHL Plus) in June 2016 
without language restriction and using the explosion function if available. The publication 
year was limited to between 2000 and June 2016 since Fried’s original article outlining CHS 
criteria was published in 2001.[2] The ESRD-related search terms used, as appropriate for 
each database, are: Renal insufficiency (Medical Subject Heading (MeSH)) OR Kidney 
failure (MeSH) OR Renal insufficiency, Chronic (MeSH) OR Kidney failure, Chronic 
(MeSH) OR Dialysis (MeSH) OR Renal dialysis (MeSH) OR Dialysis patients (MeSH) OR 
Peritoneal dialysis (MeSH) OR “end stage kidney disease” OR “end stage renal disease” OR 
“” “ESRD” OR “ESRF” OR “ESKF” OR “ESKD” OR “dialysis” OR “hemodialysis” OR 
“haemodialysis” OR “peritoneal dialysis”, AND the following frailty-related terms: Frail 
elderly (MeSH) OR Frailty syndrome (MeSH) OR “frailty”. Reference lists of relevant 
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articles were also searched manually for addition studies. 
 
Study Selection 
One investigator (GK) screened the titles, abstracts, and full texts of studies identified by the 
systematic search of the literature. Studies were considered to be potentially eligible if their 
study designs were cross-sectional or prospective providing cross-sectional data on the 
prevalence of frailty based on the original or modified CHS criteria in patients with ESRD. 
The ESRD was defined for this review as stage 5 CKD or being on hemodialysis or 
peritoneal dialysis, and the patients with stage 5 CKD managed conservatively or 
supportively without dialysis treatment were not included. Studies were excluded if they 
included patients with stage 1-4 CKD and were a randomized clinical trial, review, editorial, 
comment, or conference abstract. Gray literature, such as conference abstracts, was not 
pursued in this review since it is often difficult or not possible in these situations to assess 
detailed information. The corresponding author of a potentially eligible study was contacted 
for additional data necessary for a meta-analysis. If the same or overlapping cohort was used 
by two or more studies, the one with the largest sample size was selected for this review. 
 
Data Extraction 
The following pertinent data were extracted from each eligible study by the same investigator 
(GK): first author, cohort/study name if any, country, sample size, mean age, age range, 
proportion of females, frailty criteria, modifications to the frailty criteria if any, and the 
numbers of those who were classified as frail, prefrail, and robust/non-frail. 
 
Statistical Analysis 
The numbers of an entire cohort and those who were classified as frail were extracted from 
each study and were used to calculate the pooled prevalence of frailty via a meta-analysis. A 
chi-square test was used to assess heterogeneity among the included studies. If the p value 
was less than 0.05, it was considered to have significant heterogeneity. The I2 statistic was 
used to assess the degree of heterogeneity, with an I2 value of 25%, 50%, and 75% 
considered as low, moderate, and high degrees of the heterogeneity, respectively.[28] The 
pooled prevalence of frailty was calculated using a random-effects model if heterogeneity 
was present, and by a fixed-effects model if not, along with a 95% confidence interval 
(95%CI). The Begg-Mazumdar’s test[29] and Egger’s test[30] were used to assess 
publication bias. Statistical analyses were conducted using StatsDirect (ver. 2.8, StatsDirect, 
Cheshire, UK), and the level of statistical significance was set at a p value of less than 0.05. 
 
RESULTS 
Selection Processes 
A flow chart of the study selection is shown in Figure 1. The systematic search of the three 
databases yielded 837 studies. After 260 duplicate studies were excluded, a further 553 
studies were excluded through title and abstract screening. Of the 24 studies left, 17 studies 
were excluded during the full-text review due to using the same cohorts (n=8), non-CHS 
criteria (n=5), non-ESRD patients (n=1), or being a comment (n=1), a letter (n=1), or news 
article (n=1). One study included patients receiving not only hemodialysis or peritoneal 
dialysis, but also pre-dialysis care, and was included after data on only the hemodialysis or 
peritoneal dialysis patients were provided by the authors upon request.[26] Finally, seven 
studies were included for this review. 
 
Study Characteristics 
All seven studies used modified CHS criteria to define frailty. The data were divided, based 
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on the modifications, into two study groups: (1) studies that objectively measured physical 
performance, such as gait speed and strength, as in Fried’s original paper, and (2) studies that 
substituted the self-reported questionnaire score on physical function for the physical 
performance (36-Item Short Form Survey (SF-36) Physical Functional Scale (PFS) score <75 
in this case). Three studies[21,31,32] used both objectively measured and self-reported 
criteria to measure frailty in the same cohort and were summarized in both study groups. Two 
studies each used only objectively measured[26,33] or self-reported[34,35] frailty criteria, 
respectively. Altogether, five studies were included in each study group and are summarized 
in Table 1. While one study was published in 2007,[35] the others were published in recent 
years between 2012 and 2016.[21,26,31-34] Most studies were conducted in the United 
States[21,31-35] and only one study was from the Netherlands.[26] The sample sizes ranged 
from 49[26] to 2,275.[35] The ESRD patients used by the included studies were on 
hemodialysis in five studies,[21,31-34] and on either hemodialysis or peritoneal dialysis in 
two studies.[26,35] The mean age was 54.4-65.2 years. All studies used mixed cohorts with 
men and women. Four studies were prospective[21,33-35] and three were cross-
sectional.[26,31,32] 
 
Prevalence of Frailty 
Objectively measured frailty 
High heterogeneity was observed across the studies (I2=82.6%, p<0.001). A random-effects 
model calculated the pooled prevalence of frailty among five studies using objectively 
measured CHS criteria to be 36.8% (95%CI=29.9-44.1%). 
 
Self-reported frailty 
Since a high degree of heterogeneity was observed in five studies that used self-reported CHS 
criteria (I2=96.5%, p<0.001), a random-effect model was used. The pooled prevalence was 
67.0% (95%CI=58.7-74.7%). 
 
Publication Bias Assessment 
There was no evidence of publication bias in the two study groups according to Begg-
Mazumdar’s and Egger’ tests (all p>0.2). 
 
DISCUSSION 
In 2005, Woods and colleagues modified CHS criteria to accommodate the available data 
from the Women’s Health Initiative Study (WHI).[36] In the original version of CHS criteria, 
weakness was defined as being in the lowest 20% of handgrip strength and slow walking 
speed was defined as being in the lowest 20% of usual walking speed.[2] For these two 
components, they substituted a self-reported questionnaire, the Rand-36 Physical Function 
Scale (PFS). The PFS scores range from 0 to 100, with a higher score indicating better 
physical function, and PFS<75 was considered as having two points for weakness and slow 
walking speed; PFS>75 was considered as having zero point. The modifications were 
justified by correlations of PFS with walking speed (r=0.34) and handgrip strength (r=0.14) 
in a subsample of WHI, and frailty defined by CHS criteria with Woods’ modifications 
predicted disability (OR=3.15), hospitalization (OR=1.95 for mean number of hospitalization 
per year during follow up of >0.5 compared with no hospitalization), hip fracture (HR=1.57), 
and mortality (HR=1.71).[36] 
 
This systematic review and meta-analysis identified seven studies, encompassing 5,254 
ESRD patients, and revealed that prevalence of frailty varied substantially depending on the 
modifications made to CHS criteria. While the pooled prevalence of frailty was 36.8% among 
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five studies using objectively measured CHS criteria, the self-reported CHS criteria, which 
replaced strength and gait speed with the self-reported questionnaire score, showed almost 
twice the pooled frailty prevalence of 67.0% compared to the other five studies. 
 
Three studies examined the effects of these substitutions comparing the objectively measured 
and self-reported CHS criteria in the same ESRD cohorts and all three studies showed a 
higher prevalence of frailty according to self-reported CHS criteria compared with the 
objectively measured CHS criteria.[21,31,32] Among 188 ESRD patients, while objectively 
measured CHS criteria classified 23.8% and 32.6% of the patients as having slow gait speed 
and weakness, respectively, a strikingly high proportion of the patients (80.3%, 151/188) 
were considered to have both of these components based on the substitutions of SF-36 
PFS<75.[32] As a result, the prevalence of frailty was substantially different in the 
comparisons: 23.8% by objectively measured CHS criteria vs. 78.2% by self-reported CHS 
criteria.[32] Similarly, another study showed a higher prevalence of frailty based on self-
reported CHS criteria (52.0%) compared with that based on objectively measured CHS 
criteria (31.5%) among 762 ESRD patients on hemodialysis.[21] One study lacked the data 
for weight loss and used the rest of the four components for objectively measured CHS 
criteria and meeting two or more components out of the possible four was defined as being 
frail.[31] For self-reported CHS criteria, the authors gave SF-36 PFS<75 one point, instead of 
two points as in other studies, along with one point each for exhaustion and low physical 
activity, and meeting two or more components out of the possible three was defined as 
frail.[31] Presumably due to the different modification from the other studies, the prevalence 
of frailty was similar, at 58.8% and 62.5% based on objectively measured and self-reported 
CHS criteria, respectively.[31] 
 
It is not clear why prevalence of frailty differ substantially between two sets of CHS criteria 
with different modifications. One possibility is that both of weakness and slow gait speed 
were considered to be present in only lowest 20% of the entire cohort in objectively measured 
CHS criteria, while there is no such restriction to the proportion of those with SF-36 PF of 
less than 75 points in self-reported CHS criteria, possibly leading to the higher prevalence of 
frailty. However, regardless of the modification of the CHS criteria, both objectively 
measured and self-reported CHS criteria longitudinally predicted negative health outcomes in 
ESRD populations.[20,21,34,37]  It seems too early to conclude which version of frailty 
criteria is better for risk assessment of ESRD patients with currently available knowledge, 
and further research is warranted especially regarding how longitudinal health outcomes and 
effects of frailty interventions may differ among ESRD patients defined as frail by whether 
objectively measured or self-reported CHS criteria. 
 
Most of the included studies consistently showed, regardless of whether objectively measured 
or self-reported CHS criteria are used, that frail individuals were more likely to be older and 
female and to have comorbidities,[21,26,31-35] which are in line with previous studies of 
community-dwelling elderly populations.[10] Due to the lack of grouped data by these 
factors in these studies, stratified meta-analysis was not possible. Various studies examined 
prospective risks of negative health outcomes according to frailty in patients with 
CKD[38,39] and specifically ESRD.[21,33-35] Among the studies included in this review, 
one study followed over a median of 1.7 years and found that frailty defined by both 
objectively measured and self-reported CHS criteria predicted mortality adjusted for age, 
gender, race, BMI, and comorbidity (HR=2.20, 95%CI=1.41-3.30 for objectively measured 
CHS criteria; HR=1.93, 95%CI=1.24-3.00 for self-reported CHS criteria).[21] Interestingly, 
the mortality risk of those who were classified as frail by only the self-reported criteria but 
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not by the objectively measured criteria did not reach statistical significance (HR=1.40, 
95%CI=0.82-2.38), while those who were classified as frail by both criteria had a higher risk 
of mortality (HR=2.46, 95%CI=1.51-4.01).[21] 
 
There are a few studies measuring frailty using other frailty definitions among ESRD 
populations.[26,40-42] One of the studies included in this review also used the Frailty Index 
and categorized those with a Frailty Index of >0.25, 0.08-0.25, and <0.08 as being frail, 
prefrail, and robust, respectively.[26] This study showed that 39.3% (22/56) of participants 
were frail.[26] Another study from Brazil used the Edmonton Frail Scale and showed that 
38.3% (23/60) were frail.[40] A Canadian study reported a frailty prevalence of 25.9% based 
on the Clinical Frailty Scale among 390 patients with ESRD.[41] Chao and colleagues 
applied six different criteria (Strawbridge questionnaire, Edmonton Frail Scale, FRAIL scale, 
Groningen Frail Indicator, G8 questionnaire, and Tilburg Frail Indicator) to 46 Taiwanese 
ESRD patients on hemodialysis to show that the frailty prevalence was highly variable, from 
19.6% using the FRAIL scale up to 82.6% with the G8 questionnaire.[42] 
 
The findings of this review need to be interpreted with caution due to the following 
limitations. First, only a limited number of studies were identified and included in this 
review, and more studies are needed for a more complete understanding of this high risk 
ESRD population. Second, most of the studies included in this review were conducted in the 
US and the findings may not be generalizable to other populations. Lastly, all processes, 
including the systematic literature search, screening, assessment of inclusion and exclusion 
criteria, and data extraction, were conducted by one investigator and it is still possible that 
important studies may have been missed. 
 
This study has multiple strengths. First, methodology of the systematic review was robust and 
reproducible, using multiple databases with extensive search terms and with the explosion 
function. An author of the potentially eligible study was contacted for additional data 
necessary for the meta-analysis.[26] Second, this was the first to quantitatively pool the 
prevalence of frailty among ESRD populations. Third, the meta-analysis was conducted using 
two study groups according to how the CHS criteria were modified – objectively measured 
vs. self-reported – revealing that the self-reported CHS classified nearly twice as many ESRD 
patients as being frail compared with the objectively measured ones. Given frail patients with 
ESRD are at high risks for negative health outcomes,  
 
It is worthwhile to identify frail patients with ESRD who may potentially benefit from 
interventions, such as a nutritional supplement or exercise program.[39] A randomized 
controlled trial showed that taking a CKD-specific high-protein oral nutritional supplement 
with anti-inflammatory and anti-oxidative ingredients for 16 weeks significantly improved 
serum albumin levels in patients on maintenance hemodialysis.[16] Intradialytic exercise 
training has been suggested as an effective therapy for low physical activity and 
sarcopenia.[43] Although this therapy still lacks the evidence necessary to be standard care 
for ESRD patients, it appears safe and well-tolerated, and may be beneficial especially when 
continued for more than six months.[18] 
 
Conclusion 
This systematic review and meta-analysis highlights that more than one third of ESRD 
patients were frail based on objectively measured CHS criteria, and that the prevalence of 
frailty almost doubled when using the self-reported CHS criteria. This information should be 
taken into account especially when modified CHS criteria are used in this population. 
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Figure 1. Flow chart of systematic literature review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHS: Cardiovascular Health Study 
ESRD: End-stage renal disease 
  
837 studies identified through database searching 
   Embase (n=531) 
   MEDLINE (n=233) 
   CINAHL Plus (n=73) 
577 studies screened for titles and abstracts 
24 articles for full-text review 
Total of 837 studies identified 
260 duplicate studies excluded 
553 studies excluded by title and abstract 
screening 
 
17 studies excluded by full-text review 
   Same cohort used (n=8) 
   Non-CHS criteria used (n=5) 
   Comment, letter, or news article (n=3) 
   Non-ESRD patients used (n=1)    
7 studies for meta-analysis 
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Figure 2. Forest plots of prevalence of frailty based on the Cardiovascular Health Study 
(CHS) criteria among patients with end-stage renal disease. A: Objectively measured frailty. 
B: Self-reported frailty. 
A 
 
 
B 
 
 
  
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.37 (0.30, 0.44)
Painter 2013 0.35 (0.28, 0.42)
Delgado 2013 0.59 (0.47, 0.70)
McAdams-DeMarco 2015 0.34 (0.29, 0.39)
Johansenn 2016 0.31 (0.28, 0.35)
Drost 2016 0.29 (0.17, 0.43)
proportion (95% confidence interval)
Proportion meta-analysis plot [random effects]
0.48 0.58 0.68 0.78 0.88
combined 0.67 (0.59, 0.75)
Johansen 2007 0.68 (0.66, 0.70)
Bao 2012 0.73 (0.71, 0.75)
Painter 2013 0.78 (0.72, 0.84)
Delgado 2013 0.63 (0.51, 0.73)
Johansenn 2016 0.52 (0.48, 0.56)
proportion (95% confidence interval)
13 
 
Table 1. Summary of included studies on prevalence of frailty among patients with end-stage renal disease. 
Author/Study Country Cohort Age (range) Female (%) 
modification for weakness and slow gait speed 
components of CHS criteria 
Frail Prefrail Robust 
mCHS (objectively measured)         
Drost 2016[26] Netherlands N=49* 
on hemodialysis or 
peritoneal dialysis 
65.2 (27-88) 43.2% - original criteria without modification  28.6% 
14/49 
22.4% 
11/49 
49.0% 
24/49 
Johansen 2016[21] 
ACTIVE/ADIPOSE 
USA 
 
N=762 
all on hemodialysis 
57.1 
(>18) 
40.7% - handgrip 
- 15 ft timed walk at a usual pace 
31.5% 
240/762 
- 68.5% 
522/762 
McAdams-DeMarco 2015[33] USA 
 
N=324 
within 6 months of 
hemodialysis initiation 
54.8 43.5% - handgrip 
- 15 ft timed walk 
34.0% 
110/324 
37.7% 
122/324 
28.4% 
92/324 
Delgado 2013[31] 
NEXT 
USA N=80 
all on hemodialysis 
“55” 
(-) 
37.5% - sit-to-stand test >14.5 seonds 
- gait speed <0.8m/s 
58.8% 
47/80 
- 41.3% 
33/80 
Painter 2013[32] 
REXDP 
USA N=188 
all on hemodialysis 
54.4 
(-) 
56.4% - timed chair stand: time taken to stand up and sit 
down five times<16.70s (slowest quartile) 
- 6m time walk: <0.64m/s for men>173cm and 
women>159cm and <0.75m/s for men<173cm 
and women<159cm. 
34.6% 
65/188 
- 65.4% 
123/188 
mCHS (self-reported)         
Johansen 2016[21] 
ACTIVE/ADIPOSE 
USA N=762 
all on hemodialysis 
57.1 
(>18) 
43.2% - SF-36 PF<75 for both weakness and slow gait 
(2 points) 
52.0% 
396/762 
- 48.0% 
366/762 
Delgado 2013[31] 
NEXT 
USA N=80 
all on hemodialysis 
“55” 
(-) 
40.7% - SF-36 PF<75 for both weakness and slow gait 
(1 point) 
62.5% 
50/80 
- 37.5% 
30/80 
Painter 2013[32] 
REXDP 
USA N=188 
all on hemodialysis 
54.4 
(-) 
56.4% - SF-36 PF<75 for both weakness and slow gait 
(2 points) 
78.2% 
147/188 
- 21.8% 
41/188 
Bao 2012[34] 
Comprehensive Dialysis Study 
USA N=1,576 
all on hemodialysis 
59.6 
(-) 
44.5% - SF-36 PF<75 for both weakness and slow gait 
(1 point) 
73.3% 
1155/157
6 
- 26.7% 
(nonfrail) 
421/1576 
Johansen 2007[35] 
DMMS wave 2 
USA N=2,275 
on hemodialysis or 
peritoneal dialysis 
58.2 46.6% - SF-36 PF<75 for both weakness and slow gait 
(2 points) 
67.7% 
1540/227
5 
- 32.3% 
735/2275 
*Only those who were on hemodialysis or peritoneal dialysis were included and those who were in pre-dialysis care were excluded. 
ACTIVE/ADIPOSE: A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity 
and Survival in ESRD 
DMMS: the Dialysis Morbidity and Mortality Study  
mCHS: modified Cardiovascular Health Study criteria 
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NEXT: the Nandrolone and Exercise study 
REXDP: the Renal Exercise Demonstration Project 
 
